Overzicht lopende oncologische studies​

MASTERKEY-318

A Phase 1b/2, multicenter, open-label, basket trial to evaluate the safety of talimogene Laherparepvec Injected into liver tumors alone and in combination with systemic Pembrolizumab in Phase 1b and to evaluate the efficacy and safety of intratumoral talimogene Laherparepvec in combination with systemic Pembrolizumab to treat subjects with advanced solid tumors in Phase 2.

  • Behandeling met intratumorale injecties met T-Vec ( gemodificeerd herpes virus) in combinatie met Pembrolizumab IV.

IO-001

Phase I/Ib first-in-human study of EOS100850 in patients with advanced solid tumors.

  • Behandeling met EOS100850, een orale adenosine A2a receptor antagonist, in sommige cohorten in monotherapie, in andere cohorten in combinatie met Pembrolizumab of standard-of-care chemotherapie

TED15297

A Phase 1 first- in-human dose escalation and expansion study for the evaluation of safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of SAR441000 administered intratumorally as monotherapy and in combination with Cemiplimab in patients with advanced solid tumors

  • Intra-tumorale toediening van SAR441000, een mengsel van m-RNA’s die coderen voor cytokines, al dan niet in combinatie met Cemiplimab IV.

XL184-021

A Phase 1b dose-escalation study of Cabozantinib (XL184) administered alone or in combination with Atezolizumab to subjects with locally advanced or metastatic solid tumors.

  • Behandeling met Atezolizumab in combinatie met Cabozantinib  of - in bepaalde cohorten - Cabozantinib monotherapie.

AMG20180101

A Phase 1 study evaluating the safety, tolerability, pharmacokinetics and efficacy of prostate specific membrane antigen half-life extended bispecific T-cell engager AMG 160 in subjects with metastatic castration-resistant prostate cancer.

  • Behandeling met AMG 160 (PSMA-targeted BiTE) in monotherapie of in combinatie met Pembrolizumab.

AMG20200040

A Phase 1b study evaluating the safety, tolerability, pharmacokinetics and efficacy of delta-like protein 3 half-life extended bispecific T-cell engager AMG 757 in subjects with de novo or treatment emergent neuroendocrine prostate cancer.

  • Behandeling met AMG 757, een BiTE gericht tegen delta-like protein 3 (DLL3)

AMG20190136

A Phase 1, multicenter, open-label, dose-exploration and dose expansion study evaluating the safety, tolerability, pharmacokinetics and efficacy of AMG 994 monotherapy and combination of AMG 994 and AMG 404 in subjects with advanced solid tumors

  • Behandeling met AMG 994 (een mesotheline-afhankelijke CD40 agonist) in combinatie met AMG 404   (een anti-PD1 monoclonaal antilichaam)

RAGNAR

A Phase 2 study of Erdafitinib in subjects with advanced solid tumors and FGFR gene alterations.

  • Behandeling met Erdafitinib (FGFR inhibitor) in monotherapie.

INCB86550-102

A Phase 1 study exploring the safety, tolerability, pharmacokinetics and pharmacodynamics of INCB086550 in participants with advanced solid tumors.

  • Behandeling met INCB086550, een small-molecule PD-L1 inhibitor.

CA022-001

A Phase 1/2a first-in-human study of BMS-986218 monoclonal antibody alone and in combination with Nivolumab in advanced tumors.

  • Behandeling met BMS-986218 (anti-CTLA4-NF4), in sommige cohorten in combinatie met Nivolumab

A2A-004

A multicenter, open-label, Phase 1 clinical study to assess the safety, tolerability, pharmacokinetics and food-effect of Inupadenant new formulation in participants with advanced solid tumors.

  • Behandeling met Inupadenant, een orale adenosine A2a receptor antagonist, in monotherapie.

INCB99280-112

A Phase 1 study exploring the safety, tolerability, pharmacokinetics and pharmacodynamics of INCB99280-112 in participants with select advanced solid tumors.

  • Behandeling met INCB99280-112, een small-molecule PD-L1 inhibitor.